| Issuer | % of Class | Filed | |||
|---|---|---|---|---|---|
|
DiaMedica Therapeutics Inc.
13G/A
Amendment 4
DMAC · 25253X207
|
16.9% |
2/6/2026
Event 12/31/2025
|
|||
| Trill AB | 16.9% | ||||
| Jan Stahlberg | 16.9% | ||||
|
DiaMedica Therapeutics Inc.
13G/A
Amendment 3
DMAC · 25253X207
|
15.0% |
9/4/2025
Event 8/14/2025
|
|||
| Trill AB | 15.0% | ||||
| Jan Stahlberg | 15.0% | ||||
|
DiaMedica Therapeutics Inc.
13G/A
Amendment 2
DMAC · 25253X207
|
13.1% |
7/30/2025
Event 7/23/2025
|
|||
| Trill AB | 13.1% | ||||
| Jan Stahlberg | 13.1% | ||||
Includes filings since 12/18/2024, when the SEC began requiring structured 13D and 13G data.